pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX
MBX Biosciences
MBX Biosciences clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Carmel, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 7
- Drugs
- 3
- Patents
- 0
MBX Biosciences projects
7 ClinicalTrials.gov programs sponsored by MBX Biosciences.
MBX Biosciences has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
400 µg of MBX 2109 once-weekly by subcutaneous injection
MBX Biosciences
Hypoparathyroidism
1 trial -
MBX 1416 (INN imapextide)
MBX Biosciences
Postbariatric Hypoglycemia
1 trial -
MBX 2109
MBX Biosciences
Hypoparathyroidism
1 trial -
MBX 1416 (Part A)
MBX Biosciences
Postbariatric Hypoglycemia
1 trial -
MBX 2109
MBX Biosciences
Renal Impairment
1 trial -
MBX 2109 (Part A)
MBX Biosciences
Healthy
1 trial -
MBX 4291
MBX Biosciences
Obesity
1 trial
Frequently asked questions
How many clinical projects does MBX Biosciences have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.